1. Home
  2. AMBQ vs XERS Comparison

AMBQ vs XERS Comparison

Compare AMBQ & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMBQ
  • XERS
  • Stock Information
  • Founded
  • AMBQ 2010
  • XERS 2005
  • Country
  • AMBQ United States
  • XERS United States
  • Employees
  • AMBQ N/A
  • XERS N/A
  • Industry
  • AMBQ Semiconductors
  • XERS Biotechnology: Pharmaceutical Preparations
  • Sector
  • AMBQ Technology
  • XERS Health Care
  • Exchange
  • AMBQ Nasdaq
  • XERS Nasdaq
  • Market Cap
  • AMBQ 673.1M
  • XERS 752.7M
  • IPO Year
  • AMBQ 2025
  • XERS 2018
  • Fundamental
  • Price
  • AMBQ N/A
  • XERS $5.49
  • Analyst Decision
  • AMBQ
  • XERS Strong Buy
  • Analyst Count
  • AMBQ 0
  • XERS 6
  • Target Price
  • AMBQ N/A
  • XERS $6.25
  • AVG Volume (30 Days)
  • AMBQ 2.8M
  • XERS 1.8M
  • Earning Date
  • AMBQ 01-01-0001
  • XERS 08-07-2025
  • Dividend Yield
  • AMBQ N/A
  • XERS N/A
  • EPS Growth
  • AMBQ N/A
  • XERS N/A
  • EPS
  • AMBQ N/A
  • XERS N/A
  • Revenue
  • AMBQ $76,589,000.00
  • XERS $222,551,000.00
  • Revenue This Year
  • AMBQ N/A
  • XERS $35.31
  • Revenue Next Year
  • AMBQ N/A
  • XERS $19.65
  • P/E Ratio
  • AMBQ N/A
  • XERS N/A
  • Revenue Growth
  • AMBQ 50.25
  • XERS 29.88
  • 52 Week Low
  • AMBQ $35.00
  • XERS $2.10
  • 52 Week High
  • AMBQ $51.76
  • XERS $6.07
  • Technical
  • Relative Strength Index (RSI)
  • AMBQ N/A
  • XERS 62.75
  • Support Level
  • AMBQ N/A
  • XERS $4.94
  • Resistance Level
  • AMBQ N/A
  • XERS $5.22
  • Average True Range (ATR)
  • AMBQ 0.00
  • XERS 0.22
  • MACD
  • AMBQ 0.00
  • XERS -0.01
  • Stochastic Oscillator
  • AMBQ 0.00
  • XERS 86.44

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).

Share on Social Networks: